SUBSCRIBE
SUBSCRIBE
News   Policy

ARYx Therapeutics, Inc. Says FDA Backs Anticlotting Agent Development Path

January 5, 2010 | 
1 min read
Reuters -- ARYx Therapeutics Inc said U.S. health regulators confirmed that the current development pathway for its experimental anticoagulant agent remains acceptable to seek regulatory approval.
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Man jumping, running, and winner holding trophy. Competition, challenge, risk and reward concept. Vector illustration.
Approvals
Milestone’s Long Regulatory Road Ends in Approval for Cardamyst
December 15, 2025
 · 
2 min read
 · 
Tristan Manalac
COVID-19
Prasad’s Claim of 10 Pediatric Deaths From COVID-19 Shots Overblown: Report
December 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Unvaccinated And vaccinated people as anti-vaxxer or individuals that oppose taking the vaccine with 3D illustration elements.
Vaccines
FDA Plans Black Box Warning for COVID-19 Vaccines: Report
December 12, 2025
 · 
3 min read
 · 
Heather McKenzie
Concept of freedom, with a man who opens a breach in a wall to escape from his prison and pass from the shadows to the light.
FDA
Opinion: FDA Is Built on Predictability and Expertise, Not Norm-Breaking
December 11, 2025
 · 
5 min read
 · 
Steven Grossman